meet in Biological Technology

SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements

ST. LOUIS, July 21 /PRNewswire-FirstCall/ -- SAFC Supply Solutions, a business segment of SAFC(R) ( www.safcglobal.com ), a member of the Sigma-Aldrich(R) Group (Nasdaq: SIAL ), today announced the launch of a diverse product offer ( www.safcsupplysolutions.com/molecular ) designed...

Dr. Daniel Ronel Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler

SANTA FE and ALBUQUERQUE, N.M., July 10 /PRNewswire/ -- Daniel Ronel, M.D., a board-certified plastic surgeon, has selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler for the correction of smile lines, to treat patients who are looking for a longer lastin...

ICON Central Laboratories in Singapore Moves to New Facility to Meet Growing Demand

DUBLIN, June 26 /PRNewswire-FirstCall/ -- - Singapore Laboratory Testing Increases by 149% in Past Six Months ICON plc (NASDAQ:ICLR: ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today...

CoreRx, Inc. Announces Plans for Expansions to Meet the Needs of Growing Pharmaceutical Formulation Development Business

Formulation Development firm CoreRx announces new facility which will add capacity, additional capabilities to growing laboratory in order to meet growing customer demands. Tampa, FL (Vocus) June 15, 2009 -- CoreRx, Inc. has announced plans to purchase a new facility wh...

Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries

NEWTON, Mass., June 3 /PRNewswire-FirstCall/ -- Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTC Bulletin Board: MFLU), and POWREX Corporation have entered into an exclusive distributorship agreement whereby POWREX will market, sell and service Microfluidize...

Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology

STOCKHOLM, April 27 /PRNewswire/ -- Xspray Microparticles AB, the Swedish life science technology company, has developed a cutting-edge solution for pharmaceutical particle production based on supercritical fluid technology. The Company's RightSize Particle Manufacturing Technology overcomes m...

Waters Corporation Continues to Meet Today's Challenges for Improved Laboratory Operations with New Products at Pittcon 2009

Waters Gives Scientists, Business and Laboratory Managers More of What They Want: Efficiency, Data Quality, Productivity and Profitability CHICAGO, March 9 /PRNewswire-FirstCall/ -- Against a backdrop of a worldwide economic recession, Waters Corporation (NYSE: WAT ) is demonstrating how i...

Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii)

WALTHAM, Mass., Dec. 26 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today, that on December 23, 2008 the Company received notice from the NYSE Alternext US LLC (the "the Exchange") indicating that the Company is not in compliance with certain conditions ...

DuPont Expands Seed Production Capacity to Meet Growing Demand for Seed, Grain

New Facility in Oregon Will Help Ramp Up New Corn Hybrids Faster. Des Moines, Iowa (Vocus) November 6, 2008 -– DuPont today announced plans to construct a parent seed corn production facility in Hermiston, Ore. The expansion is one of many steps DuPont business ...

Allied Healthcare Launches First of Line of Ventilators Designed to Meet Demands of Mass Casualty Incidents

ST. LOUIS, Oct. 8 /PRNewswire-FirstCall/ -- Mass casualty incidents -- such as terrorist attacks, pandemic flu outbreaks or natural calamities like earthquakes or hurricanes -- raise the life-and-death reality that existing medical equipment is not adequate to provide treatment for all who nee...

Biopure Announces Date to Meet with UK's Medicines and Healthcare Products Agency

CAMBRIDGE, Mass., May 2 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR ) today announced that a meeting with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) is scheduled for May 29, 2008 in the UK. The purpose of the meeting is to clarify the iss...

Liberty Screening Services Hires Top Executive to Meet Explosive Demand for its Background-Screening Services

HOUSTON, March 31 /PRNewswire/ -- Sherry Jones, PHR, is the new national sales director for rapidly expanding Liberty Screening Services. The company creates uniform background-screening strategies for many Fortune 500/1000 clients and smaller companies through proprietary, real-time online so...

Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint

Company to host conference call Today, Monday, March 10, 2008 at 8:30am NEW YORK, March 10 /PRNewswire-FirstCall/ -- On Friday, March 7, 2008, Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the t...

Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand

Company incorporates in U.S., grows network of partner clinics, fits dozens of patients BOSTON, MA and LIVINGSTON, Scotland, Jan. 29 /PRNewswire/ - Touch Bionics, developer of the world's first commercially available bionic hand, today announced its incorporation in ...

BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities

BIRMINGHAM, Ala., Jan. 10 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced Thomas J. Simon, M.D. has joined BioCryst as a consultant and interim Chief Medical Officer. Dr. Simon brings more than 20 years of expertise in global pharmaceutical development...

Biotechnology Needed to Help Meet Growing Global Needs for Food, Feed, Fuel and Materials, DuPont Chairman & CEO Says at World Food Prize

DES MOINES, Iowa, Oct. 19 /PRNewswire-FirstCall/ -- DuPont Chairman and CEO Charles O. Holliday, Jr., today told participants at the World Food Prize that biotechnology will enable the world to keep pace with the rapid growth in global demand for food, feed, fuel and materials. "Biotechnology...

Wisconsins tax system must adapt to meet changing technology needs

The first study of Wisconsins tax burden in 25 years was designed to answer one overriding question: Is that burden fairly distributed among the rich, the middle class and the poor? The conclusion, announced last week, was a mildly convincing yes &mndash; but that wont be the end of Wisconsins neve...

Custom RNA & RNA Isolation Services to Meet Your Specific Needs

Experienced staff designated for custom orders Flexible, optimized protocols to meet your specific needs Established network of ethical Tissue Procurement P...

AutoImmune Inc. Reports 2009 Second Quarter Financial Results

...Medical Corp. and Eli Lilly and Company recently reported that dirucotide, the lead drug covered by AutoImmune's license agreement with BioMS, did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year Phase III trial ...

ThermoGenesis Announces Expanded Collaboration With Celling Technologies

...hose contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction ...

ThermoGenesis Provides Update on Fiscal 2009 Results

...hose contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction ...

Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast

...ologies and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovat...

PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009

... The web cast will be available for 30 days, or until approximately September 12, 2009. About PharmAthene, Inc. PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapo...

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

...biopharm's plans to seek approval for the commencement of a phase I clinical trial in Fall 2009; the estimated period in which Curis will have cash to meet its operating requirements and its assumptions about factors that may positively affect such period; expectations regarding the potential benefits of ...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

... our actual results to differ materially are the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401; that the Company will be able to raise ad...

PDI Reports 2009 Second Quarter Financial Results

...signed an agreement with The Medical Affairs Company which will allow us to meet a wider variety of client demands for best-in-class field resources. This f...ficant reduction of any of our existing service contracts or the failure to meet performance goals in PDI's incentive-based arrangements with customers. In...

CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform

... architecture ensure robust automation while maintaining the flexibility to meet the quality and performance demands of clinical and pre-clinical array appl...drug discovery applications. VigeneTech has the image analysis solutions to meet these stringent requirements," Dr. Minzi Ruan, CEO of VigeneTech commented....

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

...Complete Response Letter from the FDA for INTUNIV. Shire and the FDA were not able to reach agreement on final product labeling in time to meet the PDUFA date. The FDA did not identify safety concerns regarding INTUNIV, request new clinical data or additional analyses in the Comple...

Plastics that convert light to electricity could have a big impact

...anding of which materials created under which conditions are most likely to meet the 10 percent efficiency goal. As researchers approach that threshold,...e could form bubbles and channels in a way that the resulting polymer might meet the standard. Such testing can be accomplished using a very small tool ...

Micromet Closes $80.5 Million Public Offering of Common Stock

...isk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding ...

Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure

... Young, MD, George & Linda Kaufman Chair and Professor, Cleveland Clinic, and the principal investigator on the study. "The potential of CD-NP to meet both of these objectives is a compelling scientific story, and is of particular clinical importance for the approximately two-thirds of heart failure ...

Zeus Expands International Support With New Hires

... team and take on a leadership role in Ireland. His hire is part of an overall strategy to facilitate further growth in the European market and better meet the needs of our international partners." About Zeus, Inc.: Zeus, Inc. is headquartered in Orangeburg, SC USA. Zeus is a world leader ...

OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.

...each $120 million in 2010 for electronic data capture in the phase I sector alone. Solutions for a phase I specific environment must be developed to meet their unique needs and the Logos products are designed specifically for this need. About Logos Technologies, Ltd. Logos Technologies, ...

New Director of Lab Sales for Polymathic Analytical Labs

...ts," said Chris Given, Laboratory Manager. "With Bill's expertise and proven track record, we will be better able to assess the needs of our partners, meet customer demands and maintain lasting business relationships." Kerr is a graduate of the University of Pittsburgh with a B.A. in Business Admin...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...isk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding ...

International Milk Genomics & Human Health Symposium Speaker Program Announced

...ational experts in nutrition, genomics, bioinformatics and milk to address the status of milk-specific genomic research. Members of the IMGC also will meet to set future meeting agendas. The event kicks off with an industry-focused session including speakers Erik Mullaart of CRV BV addressing the sele...

Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia

...p a protocol for an additional Phase 3 trial that is designed to satisfy the FDA's request for additional efficacy information. The Company intends to meet with and work closely with the Agency to design and establish a protocol under a Special Protocol Assessment. The company anticipates that initiation ...

PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

...tained in this press release does not constitute an offer for the sale of any securities. About PharmAthene, Inc. PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapo...

China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations

...00 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com . Safe Harbor Statement Under the ...

Micromet Announces Pricing of Public Offering of Common Stock

...isk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding ...